ライフサイエンスコーパス: arm

1 ATRP) and hexamethylene diamine (as a spacer arm).

2 tating arm) or initiated everolimus (control arm).

3 s containing artemisinin or a derivative (76 arms).

4 hibitor (S3I-201 or micellar curcumin, eight arms).

5 r three cycles was worse in the experimental arm.

6 P = .001) compared with those in the control arm.

7 inferior in the DPL arm compared with the DP arm.

8 ed trials in which sorafenib was the control arm.

9 he intervention (n = 76) or control (n = 76) arm.

10 amics, as well as the dynamics of a two-link arm.

11 reatment arm, when compared with the control arm.

12 emained: 417 in the FS arm and 418 in the FV arm.

13 ction, >1) were only present in the STOP-CTX arm.

14 ML-DS 2006 trial and the historical control arm.

15 when performing these movements with either arm.

16 umab alone arm and week 6 in the combination arm.

17 by age, trial, follow-up time, and treatment arm.

18 washout, and then crossed over to the other arm.

19 did not differ with age in either treatment arm.

20 ed according to tumor location and treatment arm.

21 tion arm; and women allocated to the control arm.

22 (2.8 to 8.5 years) compared with the control arm.

23 Seventeen PICUs in the intervention arm.

24 lump in the subcutaneous tissue of the left arm.

25 similar to those of viruses from the placebo arm.

26 no significant differences between treatment arms.

27 ot differ between the flecainide and placebo arms.

28 ted information on differences in GL between arms.

29 nd activity of Aurora B kinase on chromosome arms.

30 increased risk of bleeding in both treatment arms.

31 after refractive surgery in the 2 treatment arms.

32 o (OR, 0.58; 95% CI, 0.37 to 0.93; P = .023) arms.

33 currence of adverse events between treatment arms.

34 d thereby destroys cohesion along chromosome arms.

35 and vancomycin (128 [71%] of 181) treatment arms.

36 sion of ER stress-induced bZIP28/IRE1-bZIP60 arms.

37 not the control (76.0% vs 76.6%, P = 0.726) arms.

38 R1 were associated with pCR in all treatment arms.

39 tion in the number of outer and inner dynein arms.

40 not significantly different between the two arms.

41 as not significantly different between trial arms.

42 site clearance time was 24 hours in both the arms.

43 inidase and selective extension of the other arms.

44 olerability profiles were comparable between arms.

45 ct with the environment, as when we move our arms.

46 In Panel 3-Arm 1 and Panel 3-Arm 2, 6/7 (86%) GT1a + ribavirin and

47 lan-Meier estimates of PTDM were similar for arm 1 versus arm 2 (17.4% vs 16.6%; P = 0.579).

48 luster-randomized effectiveness trial with 4 arms: 1) LNSs during pregnancy and the first 6 mo postpa

49 ducator-FSW groups were randomized to 1 of 3 arms: (1) delivery (direct distribution of an oral HIVST

50 d (646 in the laboratory arm, 651 in the POC arm), 159 (12.4%) of whom had culture-positive PTB.

51 imates of PTDM were similar for arm 1 versus arm 2 (17.4% vs 16.6%; P = 0.579).

52 In Panel 3-Arm 1 and Panel 3-Arm 2, 6/7 (86%) GT1a + ribavirin and 4/8 (50%) GT1b wit

53 s without cirrhosis were randomized to three arms: 200 mg GLE + 80 mg PIB (arm A), 300 mg GLE + 120 m

54 relapse risk in the GO arm than in the No-GO arm (26% v 49%; P < .001).

55 wer in the SCRT arm compared with the ConvRT arm (29% vs 52%; P = .02).

56 12.60 kg, P = 0.056) and the TAC elimination arms (4.76 +/- 9.94 kg, P = 0.007).

57 n due to adverse events were similar in both arms (6% lapatinib and 5% placebo).

58 viduals were enrolled (646 in the laboratory arm, 651 in the POC arm), 159 (12.4%) of whom had cultur

59 ne was higher at month 12 in the TAC control arm (8.15 +/- 9.27 kg) than in the EVR + reduced TAC (5.

60 for the intensive compared with the standard arm (95% confidence intervals) were 1.18 (0.40 to 3.33),

61 A compared with 82% in arm B (difference vs arm A 6.6%; 95% CI 4.8-8.3) and 84% in arm C (8.5%, 6.8-

62 The estimated OPV coverage was 75% in arm A compared with 82% in arm B (difference vs arm A 6.

63 assigned to celecoxib (400 mg twice per day; arm A) or placebo (arm B).

64 mized to three arms: 200 mg GLE + 80 mg PIB (arm A), 300 mg GLE + 120 mg PIB with 800 mg once-daily R

65 , 2014, 387 clusters were randomised (131 to arm A, 127 to arm B, and 129 to arm C).

66 ildren younger than 5 years were recorded in arm A, 30 098 in arm B, and 29 126 in arm C.

67 ren younger than 24 months of age was 43% in arm A, 52% in arm B (9%, 7-11) and 54% in arm C (11%, 9-

68 patients with mCRPC were randomly assigned: arm A, n = 72; arm B, n = 76.

69 n unintended outcome was observed in the FFV arm: a negative intervention effect on mean haemoglobin

70 ARM allows frequent identification of arm lymphatics in

71 The 45 patients in the experimental arm also underwent abdominopelvic (18)F-fluciclovine PET

72 irty-eight patients (39%) in the combination arm and 18 patients (18%) in the ipilimumab arm had an o

73 , 835 (82%) children remained: 417 in the FS arm and 418 in the FV arm.

74 2-year LRC rate was 58.5% in the once-a-week arm and 73.1% in the once-every-3-weeks arm, leading to

75 within 30 days were 76.5% in the laboratory arm and 79.5% in the POC arm (odds ratio, 1.13; 95% conf

76 ing a simulation of a two-joint planar robot arm and an optimisation algorithm was used to find the o

77 The difference between single-arm and double-arm configurations has been investigated

78 nase (TbPLK), which is essential for centrin arm and FAZ duplication.

79 paralysed arm to perform simple single-joint arm and hand movements and functionally meaningful multi

80 sponsible for the dexterous control of human arm and hand movements.

81 doses) began week 1 in the ipilimumab alone arm and week 6 in the combination arm.

82 ent factor H (CFH) are also features of both ARMD and TMA, we hypothesized that VEGF and CFH interact

83 showed greater number of entries into closed arms and center compared to controls and those exposed t

84 imab alone (same schedule as the combination arm) and with a final sample size of 454 patients.

85 n = 100 in the AL arm, n = 102 in the CQ+PQ arm, and n = 92 in the AL+PQ arm) were followed for 1 y,

86 ng a group but allocated to the intervention arm; and women allocated to the control arm.

87 three G-actin-binding sites (GABs) on other arms are available to recruit and deliver monomers to th

88 mputer interface (BCI) controlled prosthetic arms are being developed to restore function to people w

89 tional parameters was compared between the 2 arms as the primary end point and overall survival (OS)

90 aft trial) some women in the standard repair arm assigned to all treatment options were included in t

91 eaths in the ultralow-risk tamoxifen-treated arm at 15 years, and these patients had a 20-year diseas

92 26, 0.071, 0.170 and 0.389% per mmHg for the arm at 45 degrees from the horizontal level, confirming

93 10, 0.029, 0.054 and 0.108% per mmHg for the arm at the horizontal level, and 0.026, 0.071, 0.170 and

94 population size and composition, exposure to armed attacks, sexual and gender-based violence, food se

95 For the 20-minute incubation arm, average AK clearance was 76% vs 58% on the sham sid

96 an 24 months of age was 43% in arm A, 52% in arm B (9%, 7-11) and 54% in arm C (11%, 9-13; overall p<

97 verage was 75% in arm A compared with 82% in arm B (difference vs arm A 6.6%; 95% CI 4.8-8.3) and 84%

98 In the absence of progression, patients in arm B continued bevacizumab alone until disease progress

99 The response rate for arm B was 60% (complete, 10%; partial, 50%), which is hi

100 GLE + 120 mg PIB with 800 mg once-daily RBV (arm B), or 300 mg GLE + 120 mg PIB without RBV (arm C).

101 ib (400 mg twice per day; arm A) or placebo (arm B).

102 usters were randomised (131 to arm A, 127 to arm B, and 129 to arm C).

103 an 5 years were recorded in arm A, 30 098 in arm B, and 29 126 in arm C.

104 mCRPC were randomly assigned: arm A, n = 72; arm B, n = 76.

105 with ventral striatum (VS) lesions on a two-arm bandit task that had randomly interleaved blocks of

106 By contrast, during FG, the arm became actively involved in driving body sway, as re

107 d for HIV than those in the standard of care arm, both at 1 month (risk ratio [RR] 1.33, 95% CI 1.17-

108 mbocytopenia were prolonged in the intensive arm, but there were no differences in serious nonhematol

109 in arm A, 52% in arm B (9%, 7-11) and 54% in arm C (11%, 9-13; overall p<0.0001).

110 ce vs arm A 6.6%; 95% CI 4.8-8.3) and 84% in arm C (8.5%, 6.8-10.1; overall p<0.0001).

111 ised (131 to arm A, 127 to arm B, and 129 to arm C).

112 B), or 300 mg GLE + 120 mg PIB without RBV (arm C).

113 al, 50%), which is higher than the 43.3% for arm C.

114 ded in arm A, 30 098 in arm B, and 29 126 in arm C.

115 mass of the object alters the physics of our arm, changing the relationship between motor commands th

116 ion in wet age-related macular degeneration (ARMD), choriocapillaris degeneration, and glomerular thr

117 tings, it has been assessed via the midupper arm circumference (MUAC) with a cutoff <115 mm for sever

118 We did a community-based three-arm cluster randomised trial in healthy children aged 1

119 HIV self-test use was higher in the delivery arm compared to the coupon arm (RR = 1.14, 95% CI 1.05-1

120 severe adverse events was 0.6% in the e-POCT arm compared with 1.5% in the ALMANACH arm (RR 0.42, 95%

121 ine was also significantly lower in the SCRT arm compared with the ConvRT arm (29% vs 52%; P = .02).

122 edian OS was found to be inferior in the DPL arm compared with the DP arm.

123 evalence increased over time in the STOP-CTX arm, compared with the CTX arm, with values of 4% and <1

124 The difference between single-arm and double-arm configurations has been investigated experimentally.

125 a treatment trials (n = 40) with monotherapy arms containing artemisinin or a derivative (76 arms).

126 nts were randomized equally into 2 treatment arms (control and intervention).

127 rotocol was amended to continue with a three-arm design (1:1:6 ratio), with a new arm that included r

128 The ARMS designation accounted only for a small proportion o

129 in the dimeric structure (i.e. the prodomain arm domain and GF domain in each monomer are swapped).

130 odel building demonstrate that the prodomain arm domain in one monomer is linked to the GF that inter

131 is linked to the GF that interacts with the arm domain in the other monomer in the dimeric structure

132 multicenter randomized trial with 2 parallel arms (drain vs no drain) was performed between 2011 and

133 This body outline confirms patagia-bearing arms, drumstick-shaped legs and a slender tail, features

134 FT-B but does not support transport of outer arm dynein into flagella.

135 42%] of 31 patients) than in the eltrombopag arm (eight [14%] of 59 patients; p=0.0025).

136 ticipants were randomized into 2 incubations arms, either 10-minute or 20-minute aminolevulinic acid

137 c emission, with green emission from the CdS arms emerging only at high excitation fluences.

138 eas the IgG4 isotype can undergo in vivo Fab arm exchange leading to bispecific antibody and off-targ

139 reduced in the DP-PQ arm relative to the DP arm (females: 0.05% [interquartile range {IQR}, 0.0-0.7%

140 (5 mL) is injected in the ipsilateral upper arm for localization of nonbreast lymphatics.

141 ily tuned with different number of eggbeater arms for potential applications such as micro hand for d

142 oke conformation without directing the lever arm forward; and second, the lever arm reaches the posts

143 tibody-recruiting molecules targeting fungi (ARM-Fs).

144 onships strongly influence the style of high-arm grooming in wild chimpanzees of the Kanyawara commun

145 arm and 18 patients (18%) in the ipilimumab arm had an objective response (odds ratio, 2.9; 95% CI,

146 More patients in the 33 degrees C treatment arm had hyperglycemia.

147 patients in 200 mg and 41 patients in 600 mg arms) had clinical remission versus six (15%) of 39 plac

148 t that the schedules used in the three trial arms have almost identical efficacies, but slight modifi

149 TBSA and the need for grafting of the arm, head/neck, and trunk were significant predictors of

150 recently showed no difference between study arms in acute GVHD-free survival.

151 s arm to infected mosquitoes in the standard arm-in-cage assay.

152 After multivariable adjustment, treatment arm independently predicted MI at months 12 to 15 (P<0.0

153 functional, it should operate only when the arm is being controlled in an earth-fixed rather than a

154 When the receiving arm is charged with KCN, transport is much faster (ca. 1

155 Alveolar rhabdomyosarcoma (ARMS) is a devastating pediatric disease driven by expre

156 week arm and 73.1% in the once-every-3-weeks arm, leading to an absolute difference of 14.6% (95% CI,

157 An early imbalance in TE events in the PAG arm led to a clinical hold; thereafter, patients with TE

158 Both intervention arms led to improved parental resource empowerment: 0.29

159 ARM allows frequent identification of arm lymphatics in the axilla, which would have been tran

160 and working memory evaluated using a radial arm maze.

161 52 patients were randomized to the rotating arm (median [range] age, 65 [44-87] years) and 49 patien

162 44-87] years) and 49 patients to the control arm (median [range] age, 67 [38-82] years).

163 There was no OS benefit in the experimental arm (median, 21.8 v 24.5 months; hazard ratio, 1.38; 95%

164 in hypoxia induced H9c2 cardiac cells using ARM microcontroller.

165 frequently caused by non-assembly of dynein arm motors into cilia and flagella axonemes.

166 patterns were similar across right and left arm movements to identical targets (extrinsic coordinate

167 We armed MSCs with different oHSV variants (MSC-oHSV) and f

168 ed controlled, open-label trial with a multi-arm, multi-stage design.

169 This prospective, single-arm, multicenter study was conducted from November 2012

170 We conducted a 3-arm, multicentre randomised controlled trial in primary-

171 n motor commands that our brain sends to our arm muscles and the resulting motion of our hand.

172 survival) in the optimal medical management arm (n=103) and HMRS-predicted versus observed survival

173 A total of 398 patients (n = 104 in the CQ arm, n = 100 in the AL arm, n = 102 in the CQ+PQ arm, an

174 ts (n = 104 in the CQ arm, n = 100 in the AL arm, n = 102 in the CQ+PQ arm, and n = 92 in the AL+PQ a

175 % in the laboratory arm and 79.5% in the POC arm (odds ratio, 1.13; 95% confidence interval, 0.51-2.5

176 g of the intrinsically disordered C-terminal arm of CcdA to the toxin CcdB prevents CcdB from inhibit

177 Among the SHK arm of our study, 5-year graft survival (72% [SHK] vs 73

178 receptor (BMPR) axis: the anti-proliferative arm of TGF-beta super family of receptors.

179 critical for the pathological, EMT-inducing arm of TGFbeta signaling.

180 In the Lipid-Lowering Arm of the Anglo-Scandinavian Cardiac Outcomes Trial, pa

181 a marker for activation of the inflammatory arm of the contact system, is increased in a mouse model

182 oteostatic machinery and the IRE1-alpha-MKK4 arm of the endoplasmic-reticulum-stress-response pathway

183 ell response while increasing the regulatory arm of the immune response in animals models of autoimmu

184 tion did not allow the staff to be masked to arm of the trial; however, randomisation was done in bat

185 kidney function in the intensive BP lowering arm of two trials in CKD associated with higher risk of

186 her-infant pairs receiving all 3 recommended arms of antiretroviral prophylaxis or treatment (prenata

187 s and autophagy are evolutionarily conserved arms of cell-autonomous immunity that restrict replicati

188 plus cetuximab and FOLFIRI plus bevacizumab arms of FIRE-3.

189 pplying exclusions gave 39 publications in 3 arms of patient populations (adult, pediatric, and mixed

190 The unprotected regressed arms of reversed forks are the entry point for MRE11 in

191 ined neuronal tracer injections into various arms of the circuit through specific DA subpopulations t

192 e preference, and decreased time in the open arms of the elevated plus maze relative to control mice.

193 n exaggerated activation of the proapoptotic arms of the endoplasmic reticulum stress response that i

194 iding a better understanding of how multiple arms of the immune system cooperate to achieve an optima

195 ard and regulatory interactions between both arms of the immune system.

196 By the end of therapy, the two arms of therapy had no significant differences in any of

197 We conducted a single-arm, open-label study in which 15 virologically suppress

198 In this single-arm, open-label trial, we enrolled virologically suppres

199 Single-arm, open-label, multicenter clinical study.

200 We did this single-arm, open-label, multicentre phase 3 study at 40 sites i

201 e 121 patients (36.4%) in the noncarboplatin arm (OR, 2.14; 95% CI, 1.28-3.58; P = .004).

202 ib 800 mg/d and everolimus 10 mg/d (rotating arm) or continuous pazopanib 800 mg/d (control arm) unti

203 atment (ART) randomized to continue (the CTX arm) or discontinue (the STOP-CTX arm) were examined for

204 azopanib or everolimus monotherapy (rotating arm) or initiated everolimus (control arm).

205 able viral load but only 58.3% in the DRVrtv arm (P = .003).

206 versus placebo within the first 14 days were arm pain (57.4% [27 of 47] vs 7.4% [seven of 94]) and lo

207 ficantly improved at follow-up while control arm patients' self-efficacy declined.

208 m (RPE) of age-related macular degeneration (ARMD) patients and therefore could be an attractive ther

209 tron) and multiarm PEG macromolecules (eight-arm PEG20K-NH2 and eight-arm PEG40K-NH2) at 3.2, 16, and

210 cromolecules (eight-arm PEG20K-NH2 and eight-arm PEG40K-NH2) at 3.2, 16, and 16 ng mL(-1), respective

211 urable safety and efficacy results in single-arm phase 1 and 2 studies.

212 A single arm phase 2 clinical trial of 15 patients with breast ca

213 This US-based, multicentre, single-arm, phase 2 prevention study enrolled women aged 18 yea

214 EF was an international, multicentre, single-arm, phase 2 trial done at 29 centres in eight European

215 lind, randomised, parallel-controlled, three-arm, phase 3, multicentre study done at 143 sites in 17

216 Results A rolling-arms platform design with two to five experimental treat

217 with a thiol-activated terminal such as four-arm poly(ethylene glycol)-thiol (PEG-SH) via chemisorpti

218 despite the same chair movement profile and arm posture.

219 ecules and organs used in the coevolutionary arms race between predator and potential prey.

220 two frequent outcomes of the plant-herbivore arms race.

221 de strong evidence for a contemporary sexual arms race.

222 tacean ecology, such as trophic dynamics and arms races, have an evolutionary basis that remains most

223 tudy was an investigator-blinded, 6-month, 2-arm randomized clinical trial conducted between January

224 We performed a parallel-arm randomized controlled trial to test whether administ

225 the lever arm forward; and second, the lever arm reaches the poststroke orientation by undergoing a r

226 Moreover, both arms received standardized therapeutic decision-making,

227 ractions between Taz1-associated chromosomal arm regions and telomeres.

228 nsity was significantly reduced in the DP-PQ arm relative to the DP arm (females: 0.05% [interquartil

229 utilized by its cortical neighbor (residual arm representation), depending on residual arm usage in

230 sed ribosomes, certain tRNAs with specific d-arm residues must be present in the peptidyl site, e.g.,

231 s were 9.5% and 9.2% for the 400- and 800-mg arms, respectively, and the estimated 10-year overall su

232 ed randomly into the albendazole and placebo arms, respectively.

233 OS was 67.3% and 69.6% in the N3I1 and N1I3 arms, respectively.

234 d 61.7% of the patients in the N3I1 and N1I3 arms, respectively.

235 bular stimulation, indicating a compensatory arm response to a sensation of altered body motion.

236 e immune response, as deficiencies in either arm result in reduced tumor control.

237 tion is almost flat, implying that the lever arm rotation is mostly uncoupled from the motor domain.

238 -POCT arm compared with 1.5% in the ALMANACH arm (RR 0.42, 95% CI 0.20, 0.87, p = 0.02).

239 0.001) and those in the facility collection arm (RR 1.22, 95% CI 1.08-1.37, p = 0.001).

240 e for HIV than those in the standard of care arm (RR 1.51, 95% CI 1.29-1.77, p < 0.001) and those in

241 r in the delivery arm compared to the coupon arm (RR = 1.14, 95% CI 1.05-1.23, P = 0.001) at 1 month,

242 ily-specific information in the space within arm's reach, or whether they also show a bias for inform

243 urface, or pictures of hands and feet within arm's reach, patients with complex regional pain syndrom

244 reproduce measured PNS thresholds of two leg/arm solenoid coils with good agreement.

245 he star polyMOC network is composed of tetra-arm star polymers functionalized with ligands on the cha

246 atalysis, led to a resurgence of interest in ArMs starting in the early 2000's.

247 ment by up to 30% compared with standard two-arm studies.

248 We did a phase 2, open-label, single-arm study at six centres (hospitals and cancer clinics)

249 ochore, not at damage sites along chromosome arms, such that the APC is fully inhibited within 30 min

250 The participant used a motorised mobile arm support for gravitational assistance and to provide

251 The topical arm tested 0.1% gentamicin ointment or placebo applicati

252 The intradermal arm tested daily intradermal injection of gentamicin sol

253 limited class of nanocrystals, CdSe/CdS core/arm tetrapods exhibit the unusual trait of two-colour (r

254 d significantly lower relapse risk in the GO arm than in the No-GO arm (26% v 49%; P < .001).

255 h inhibition of the SA-dependent IRE1-bZIP60 arm that antagonizes organ growth; CPR5 also favors grow

256 a three-arm design (1:1:6 ratio), with a new arm that included rituximab alone (same schedule as the

257 rotubules (MTs) and active springs that have arms that cross-link neighboring MT pairs and move unidi

258 In the noncarboplatin arm, the pCR rate was 66.7% (16 of 24) for patients with

259 range of non-natural reactions catalyzed by ArMs, this was done using a functional-group transformat

260 ncerns related to exposing a human subject's arm to infected mosquitoes in the standard arm-in-cage a

261 ability to cortically command his paralysed arm to perform simple single-joint arm and hand movement

262 Mapping of the sequenced arms to a reference transcriptome identifies the exact l

263 entails that tetrameric VASP uses one of its arms to processively track growing filament barbed ends

264 he potential that directs the rotating lever arm toward the poststroke conformation is almost flat, i

265 e increased by VEGF antagonism, a common wet ARMD treatment, suggesting that VEGF inhibition could re

266 ng single-centre, two-stage, phase 2, single-arm trial, patients (aged >/=16 years) with histological

267 Purpose Two previous single-arm trials have drawn conflicting conclusions regarding

268 units are then transported to the receiving arm until equilibrium is reached (up to 22 d).

269 m) or continuous pazopanib 800 mg/d (control arm) until progression.

270 l arm representation), depending on residual arm usage in daily life to substitute for the missing ha

271 ere randomized to one of the following study arms: view a one minute family video message, view a one

272 A2 mutations achieved pCR in the carboplatin arm vs 44 of the 121 patients (36.4%) in the noncarbopla

273 ble patients necessary in each randomization arm was estimated to be 190, and an outcomes analysis wa

274 ind that although viruses from the tenofovir arm were 2-fold less infectious, they replicated at rate

275 Women in the intervention arm were more likely to rate their delivery and postnata

276 Participants in the direct provision arm were significantly more likely to have tested for HI

277 months, participants in the direct provision arm were significantly more likely to have tested twice

278 Median patient DOTs in the PPA and PPRF arms were 8 and 6 DOT per 1000 PD, respectively (P = .03

279 The three intervention arms were as follows: standard cash (SC), a cash transfe

280 ey were not RCTs, the antibiotics in the two arms were not the same, neither mortality nor clinical e

281 267 patients were randomized, and the study arms were well matched at baseline.

282 e (the CTX arm) or discontinue (the STOP-CTX arm) were examined for malaria parasites by quantitative

283 02 in the CQ+PQ arm, and n = 92 in the AL+PQ arm) were followed for 1 y, and recurrent episodes were

284 ere as cohesion is released on the chromatid arms when the homologs segregate at anaphase I.

285 P < 0.01) were demonstrated in the treatment arm, when compared with the control arm.

286 ersistent hotspot, not associated with study arm, where S. mansoni infection prevalence and intensity

287 in the control of reaching movements of the arm, whereas the ventral premotor cortex (PMv) has been

288 lit parts of DNAzyme at each end of the four arms which, in the presence of hemin, form catalytic hem

289 her is stabilized via a conserved C-terminal arm, which may interact with the portal protein during m

290 We assessed the impact of treatment arm with a modified intention-to-treat analysis, using m

291 In preclinical studies CD276 ADCs armed with a conventional MMAE warhead destroyed CD276-p

292 ities of RAS that thwarted past efforts, and armed with new technologies and directions, the field is

293 s dilutes the number of the CRISPR complexes armed with the most recent and thus most useful spacers.

294 an overall survival was similar between both arms with 10.03 months on PaCE and 10.37 months on CE (

295 rtion of relapse was significantly higher in arms with thrice weekly therapy throughout (6.8; 95% con

296 1-12.6), and ADR (10.0; 95% CI, 2.1-46.7) in arms with thrice weekly throughout and higher rates of f

297 nt in overall survival (OS) for the eribulin arm, with a manageable toxicity profile.

298 ncer incidence in the PLCO chest radiography arm, with sensitivities >79.8% and specificities >62.3%.

299 e in the STOP-CTX arm, compared with the CTX arm, with values of 4% and <1%, respectively, at month 3

300 ng a group and allocated to the intervention arm; women not attending a group but allocated to the in